John Gerard Geisler PhD

Dr. Geisler comes with 25+ years of research experience with a consistent pharmacological focus of trying to work at the root of problems; 15-years focused on metabolic drug discovery for Pfizer, Isis, JnJ. Dr. Geisler has expertise in mitochondrial energy expenditure from years of attempting to partition lipids to restore insulin sensitivity and reduce the comorbidities associated with the “over-nutritional phenotype”. From this work, stemmed a broader understanding of new mitochondrial targeted applications, and significant gaps of pharmacological interventions for insidious movement disorders and neurodegenerative diseases.

Dr. Geisler is the author of over 50 papers & abstracts, and the co-inventor on a number of patents. Dr. Geisler holds a Ph.D. in Mammalian Genetics from University of Tennessee, conducted at Oak Ridge National Laboratories (ORNL), with a dissertation on the characterization of a novel muscle protein with dystrophin-like characteristics. His fellowship at Yale University, focused on the protective effects of E2 related to diabetic sexual dimorphism, by studying islet biology, physiology and whole-body flux of male diabetic models, supplemented with E2, which resolved diabetes.